Good Prospects For Athenex/Almirall Following PhIII Actinic Keratosis Results

Two Phase III studies of KX2-391 to treat actinic keratosis of the face and scalp met their primary endpoint of 100% clearance. The treatment could prove more convenient than marketed therapies.

SC1807_Big-Sun_125260289_1200.jpg
Sunny outlook for sun spot ointment • Source: Shutterstock

Athenex Inc. and its partner Almirall SA have achieved the primary endpoint of 100% clearance of actinic keratosis lesions at Day 57 in two Phase III trials of the topical ointment KX2-391. Data details are yet to be unveiled, but based on earlier trial results the drug is thought to be less efficacious than some marketed therapies. Nevertheless, its ease of administration and favorable local skin reaction profile position it well to take market share.

Informa's Biomedtracker raised its likelihood of approval estimate by eight percentage points to 70% after the positive trial results were...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By 

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By 

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D